🇺🇸 FDA
Pipeline program

BXCL501

BXCL501-401

Phase 3 small_molecule completed

Quick answer

BXCL501 for Agitation,Psychomotor is a Phase 3 program (small_molecule) at BioXcel Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
BioXcel Therapeutics
Indication
Agitation,Psychomotor
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials